Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

NCT04304560 is registered in ClinicalTrials.gov with Damanhour University as lead sponsor.

NCT NCT04304560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04304560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
Lead sponsor
Damanhour University
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2020
Completion date
April 30, 2021
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathies, diabete type 2, heart failure with reduced ejection fraction (hfref)